Recent Quotes
My Watchlist
Indicators
New Hampshire Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Agendia

Agendia Unveils New Real-World-Evidence from FLEX, Highlighting the Expanding Utility of MammaPrint® and BluePrint® for Predicting Neoadjuvant Chemosensitivity and Potential Resistance to CDK4/6 Inhibition in Early-Stage Breast Cancer at SABCS 2024
From Agendia
Via Business Wire
Agendia Announces New Data Assessing the Immune Active State in HR+/HER2- Early-Stage Breast Cancer at 2024 ASCO
From Agendia
Via Business Wire
Agendia to Unveil Robust Suite of Data at 2024 ASCO to Further Advance Breast Cancer Care
From Agendia
Via Business Wire
Agendia Level 1B Evidence Shows MammaPrint® is the First and Only FDA-cleared Gene Expression Profiling Test to Predict Benefit from Extended Endocrine Therapy in Early-Stage Breast Cancer Patients
From Agendia
Via Business Wire
Agendia Appoints Farida Peters-Abbadi as Vice President of Marketing
From Agendia
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.